Concord Biotech IPO vs Senco Gold IPO

Comparison between Concord Biotech IPO and Senco Gold IPO.

IPO Details

Concord Biotech IPO is a Mainboard Bookbuilding IPO proposed to list at BSE, NSE while Senco Gold IPO is a Mainboard Bookbuilding proposed to list at BSE, NSE.

Issue Size and Price

The total issue size of Concord Biotech IPO is up to ₹1,550.52 Cr whereas the issue size of the Senco Gold IPO is up to ₹405.00 Cr. The final issue price of Concord Biotech IPO is ₹741.00 per share and of Senco Gold IPO is ₹317.00 per share.

 Concord Biotech IPOSenco Gold IPO
Face Value₹1 per share₹10 per share
Issue Price (Lower)₹705.00 per share₹301.00 per share
Issue Price (Upper)₹741.00 per share₹317.00 per share
Issue Price (Final)₹741.00 per share₹317.00 per share
Discount (Retail)₹0.00 per share₹0.00 per share
Discount (Employee)₹70.00 per share
Market Lot Size20 shares47 shares
Fresh Issue Size0 shares85,17,350 shares
Fresh Issue Size (Amount)up to ₹0.00 Crup to ₹270.00 Cr
OFS Issue Size2,09,25,652 shares42,58,675 shares
OFS Issue Size (Amount)up to ₹1,550.52 Crup to ₹135.00 Cr
Issue Size Total2,09,25,652 shares1,27,76,025 shares
Issue Size Total (Amount)up to ₹1,550.52 Crup to ₹405.00 Cr

IPO Timetable

Concord Biotech IPO opens on Aug 04, 2023, while Senco Gold IPO opens on Jul 04, 2023. The closing date of Concord Biotech IPO and Senco Gold IPO is Aug 08, 2023, and Jul 06, 2023, respectively.

 Concord Biotech IPOSenco Gold IPO
Anchor Bid DateAug 03, 2023Jul 03, 2023
Issue OpenAug 04, 2023Jul 04, 2023
Issue CloseAug 08, 2023Jul 06, 2023
Basis Of Allotment (Tentative)Aug 11, 2023Jul 11, 2023
Initiation of Refunds (Tentative)Aug 14, 2023Jul 12, 2023
Credit of Share (Tentative)Aug 17, 2023Jul 13, 2023
Listing date (Tentative)Aug 18, 2023Jul 14, 2023
Anchor Lockin End date 1Sep 10, 2023Aug 10, 2023
Anchor Lockin End date 2Nov 09, 2023Oct 09, 2023

Financials & KPIs

Concord Biotech IPO P/E ratio is 32.29, as compared to Senco Gold IPO P/E ratio of 15.53.

 Concord Biotech IPOSenco Gold IPO
Financials

Company Financials (Restated Consolidated)

Period Ended31 Mar 202331 Mar 202231 Mar 2021
Assets1,513.981,312.801,182.55
Total Income888.48736.35630.75
Profit After Tax240.08174.93234.89
NET Worth1,290.001,103.22999.37
Total Borrowing31.2460.5986.35
Amount in ₹ Crore

Company Financials (Restated Consolidated)

Period Ended31 Mar 202331 Mar 202231 Mar 2021
Assets2,905.322,100.191,559.30
Total Income4,108.543,547.412,674.92
Profit After Tax158.48129.1061.48
NET Worth944.97725.77602.51
Reserves and Surplus876.27659.46536.53
Total Borrowing1,177.17862.97532.44
Amount in ₹ Crore
Promoter Shareholding (Pre-Issue)44.0876.92
Promoter Shareholding (Post-Issue)44.0868.48
P/E Ratio32.2915.53
Market Cap₹7752.06 Cr.₹2462.00 Cr.
ROE20.06%18.9%
ROCE24.27%14.2%
Debt/Equity1.25
EPS₹20.79₹22.93
RoNW20%18.96%

Shares Offered

In the Concord Biotech IPO Retail Individual Investors (RII) are offered 73,20,479 shares while in Senco Gold IPO retail investors are offered 73,20,479 shares. Qualified Institutional Buyers (QIB) are offered 41,83,130 shares in Concord Biotech IPO and 25,55,205 shares in Senco Gold IPO.

 Concord Biotech IPOSenco Gold IPO
Anchor Investor Reservation62,74,695 shares38,32,807 shares
Market Maker Reservation
QIB41,83,130 shares25,55,205 shares
NII31,37,348 shares19,16,404 shares
RII73,20,479 shares44,71,609 shares
Employee10,000 shares
Others
Total2,09,25,652 shares1,27,76,025 shares

Bids Received (Subscription)

Concord Biotech IPO subscribed 24.87x in total, whereas Senco Gold IPO subscribed 77.25x.

 Concord Biotech IPOSenco Gold IPO
QIB (times)67.67x190.56x
NII (times)16.99x68.44x
Big NII (times)19.30x72.05x
Small NII (times)12.37x61.23x
RII (times)3.78x16.28x
Employee (times)24.48x
Other (times)
Total (times)24.87x77.25x

Compare with others

Compare:

Concord Biotech IPO Vs Senco Gold IPO